The cell line is not validated yet.
SCTi003-A-5
General
iPSC Line |
|
| hPSCreg name | SCTi003-A-5 |
| Cite as: | SCTi003-A-5 |
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 11th September 2026 |
| Notes | Genome-edited Human iPSC Line, SCTi003-A-5, SNCA A53T, referred to as SCTi003-A-5, was generated by CRISPR/Cas9 technology, which introduced the SNCA A53T (c.157G>A) missense mutation into the endogenous alpha-synuclein (SNCA) locus. The A53T mutation was the first genetic mutation identified in familial Parkinson’s disease (PD) and is characterized by an increased propensity for alpha-synuclein aggregation into toxic oligomers and fibrils. This mutation is associated with early-onset Parkinsonism, rapid disease progression, and significant neurodegeneration of dopaminergic neurons (Ohgita et al.; Pushmann et al.).
This product’s parental human induced pluripotent stem cell (hiPSC) line, Healthy Control Human iPSC Line, Female, SCTi003-A (Catalog #200-0511) is a well characterized control line derived from peripheral blood mononuclear cells (PBMCs) of a 48-year-old donor. Targeted gene modifications were confirmed by Sanger sequencing. Post-editing, extensive quality control procedures were undertaken in the manufacturing process for SCTi003-A-5 to ensure optimal product performance and reproducibility. SCTi003-A-5 is karyotypically stable, expresses markers of the undifferentiated state, and remains capable of directed differentiation into all three germ layers including neural lineage cells relevant for PD research. This genome-edited hiPSC line and its isogenic parental hiPSC line provide a genetically defined tool for modeling synucleinopathy, investigating protein aggregation mechanisms, and preclinical evaluation of neuroprotective therapeutics. SCTi003-A-5 is manufactured using mTeSR™ Plus (Catalog #100-0276) and is compatible with STEMdiff™ cell culture media, allowing for standardized high-quality maintenance and differentiation to various cell types, such as midbrain neurons, astrocytes, and microglia. Cells were obtained using Institutional Review Board (IRB)-approved consent forms and protocols. |
| User feedback | |
Provider |
|
| Generator |
STEMCELL Technologies Inc. (SCT)
Contact:
STEMCELL Technologies Inc. (SCT) |
| Owner | STEMCELL Technologies Inc. (SCT) |
| Distributors | |
| Derivation country | United States |
External iPSC Databases |
|
| BioSamples | SAMEA123396601 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
Additional restrictions:
For in vitro research use only. Not approved for diagnostic, therapeutic, or clinical applications. Not approved for human or veterinary use in vivo. |
| Subclone of | |
iPSC Genetic Modification
| Disease/phenotype related modifications |
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity |
Self-declared race/ethnicity = White Ancestry = 100% European |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Is the medical history available upon request? | No |
| Is clinical information available? | No |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
External Databases (Donor) |
|
| BioSamples | SAMEA11371632 |
Ethics
Also have a look at the ethics information for the parental line
SCTi003-A
.
| Is there an MTA available for the cell line? | No |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | No |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
SCTi003-A.
|
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Proprietary non-integrating reprogramming technology |
| Is reprogramming vector detectable? |
No |
| Methods used |
PCR
|
| Notes on reprogramming vector detection | Clearance confirmed at passage 21 |
Vector free reprogramming |
|
| Type of used vector free reprogramming factor(s) |
None
|
Other |
|
| Derived under xeno-free conditions |
No |
| Derived under GMP? |
No |
| Available as clinical grade? |
No |
iPSC Culture Conditions
| Surface coating | Matrigel/Geltrex |
| Feeder cells |
No |
| Passage method |
Enzyme-free cell dissociation
ReLeSR™
|
| O2 Concentration | 20 % |
| CO2 Concentration | 5 % |
| Medium | mTeSR™ Plus |
| Has Rock inhibitor (Y27632) been used at passage previously with this iPSC line? | Yes |
| Has Rock inhibitor (Y27632) been used at cryo previously with this iPSC line? | No |
| Has Rock inhibitor (Y27632) been used at thaw previously with this iPSC line? | No |
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
|||||
| TRA 1-60 |
Yes |
SCTi003-A-5 Morphology.png
Figure 2. Cells from Human iPSC Line, SCTi003-A-5, SNCA A53T Exhibit High-Quality Morphology in Routine Culture.
Cryopreserved cells from the SCTi003-A-5 line were thawed and maintained in mTeSR™ Plus (Catalog #100-1130) on Corning® Matrigel® Matrix. Cells were cultured at 37°C and subsequently analyzed on Day 7 by brightfield microscopy. (A) The resulting iPSC colonies have densely packed cells and show multi-layering when ready to be passaged. (B,C) Cells retain prominent nucleoli and high nuclear-to-cytoplasmic ratios.
Cryopreserved cells from the SCTi003-A-5 line were thawed and maintained in mTeSR™ Plus (Catalog #100-1130) on Corning® Matrigel® Matrix. Cells were cultured at 37°C and subsequently analyzed on Day 7 by brightfield microscopy. (A) The resulting iPSC colonies have densely packed cells and show multi-layering when ready to be passaged. (B,C) Cells retain prominent nucleoli and high nuclear-to-cytoplasmic ratios.
Differentiation Potency
In vitro directed differentiation
Protocol or reference
In vitro directed differentiation
Protocol or reference
In vitro directed differentiation
Protocol or reference
Microbiology / Virus Screening |
|
| HIV 1 | Negative |
| HIV 2 | Negative |
| Hepatitis B | Negative |
| Hepatitis C | Negative |
| Mycoplasma | Negative |
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
37
|
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
|
Other Genotyping (iPSC Line) |
|
| Is there genome-wide genotyping or functional data available? |
Yes
Exome sequencing
Whole exome sequencing data file (Catalog #500-0922) is available upon request for a fee for SCTi003-A-5 customers. Please contact iPSCrequests@stemcell.com for more information.
SNP typing array
SNP microarray data is included in each lot-specific COA. Please contact iPSCrequests@stemcell.com for more information.
Genome sequencing
Whole genome sequencing data file (Catalog #500-0925) is available upon request for a fee for SCTi003-A-5 customers. Please contact iPSCrequests@stemcell.com for more information. |
Login to share your feedback, experiences or results with the research community.